Search Results - "GLICK, J. H"

Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 by Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., Senn, H.-J.

“…The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made a fundamental change in the algorithm for selection of adjuvant systemic…”
Get full text

Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer by Goldhirsch, Aron, Glick, John H., Gelber, Richard D., Senn, Hans-Jörg

“…Goldhirsch et al discuss some areas of ongoing research on breast cancer and update the adjuvant treatment recommendations presented three years ago at the 5th…”
Get full text

First—select the target: better choice of adjuvant treatments for breast cancer patients by Goldhirsch, A, Coates, AS, Gelber, RD, Glick, JH, Thürlimann, B, Senn, H-J

“…St Gallen Expert Consensus meetings update evidence on treatment of early breast cancer every 2 years and interpret its significance for treatment of…”
Get full text

Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer by Moertel, C G, Fleming, T R, Macdonald, J S, Haller, D G, Laurie, J A, Tangen, C M, Ungerleider, J S, Emerson, W A, Tormey, D C, Glick, J H

“…To determine the effectiveness of fluorouracil plus levamisole administered postoperatively to patients with resected stage II (Dukes' B2) colon cancer. This…”
Get more information

Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer by Stadtmauer, Edward A, O'Neill, Anne, Goldstein, Lori J, Crilley, Pamela A, Mangan, Kenneth F, Ingle, James N, Brodsky, Isadore, Martino, Silvana, Lazarus, Hillard M, Erban, John K, Sickles, Cheryl, Luger, Selina M, Klumpp, Thomas R, Litzow, Mark R, Topolsky, David L, Glick, John H

“…Most women with metastatic breast cancer have a response to various combinations of conventional-dose chemotherapy, but less than 5 percent of them are alive…”
Get full text

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial by Glick, J H, Young, M L, Harrington, D, Schilsky, R L, Beck, T, Neiman, R, Fisher, R I, Peterson, B A, Oken, M M

“…To compare the efficacy of sequential mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) followed by doxorubicin, bleomycin, vinblastine, and…”
Get more information

Meeting highlights: international consensus panel on the treatment of primary breast cancer by Goldhirsch, A, Wood, W C, Senn, H J, Glick, J H, Gelber, R D

Get more information

The influence of young age on outcome in early stage breast cancer by Fowble, B L, Schultz, D J, Overmoyer, B, Solin, L J, Fox, K, Jardines, L, Orel, S, Glick, J H

“…To assess the impact of young age on outcome in women with early stage breast cancer undergoing conservative surgery and radiation. Between 1981 and 1991, 980…”
Get more information

Meeting highlights: adjuvant therapy for primary breast cancer by Glick, J H, Gelber, R D, Goldhirsch, A, Senn, H J

Get more information

Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma : Results of Eastern Cooperative Oncology Group study E2479 by OKEN, M. M, HARRINGTON, D. P, ABRAMSON, N, KYLE, R. A, KNOSPE, W, GLICK, J. H

“…The Eastern Cooperative Oncology Group (ECOG) performed a Phase III comparison of melphalan and prednisone (MP) with vincristine, carmustine (BCNU), melphalan,…”
Get full text

Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer by SCHULMAN, K. A, STADTMAUER, E. A, KLUMPP, T. R, MANGAN, K. F, GLICK, J. H, REED, S. D, GLICK, H. A, GOLDSTEIN, L. J, PINES, J. M, JACKMAN, J. A, SUZUKI, S, STYLER, M. J, CRILLEY, P. A

“…We performed an economic analysis of data from 180 women in a clinical trial of conventional-dose chemotherapy vs high-dose chemotherapy plus stem-cell…”
Get full text

The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy by Markiewicz, D A, Schultz, D J, Haas, J A, Harris, E E, Fox, K R, Glick, J H, Solin, L J

“…Chemotherapy plays an increasingly important role in the treatment of both node-negative and node-positive breast cancer patients, but the optimal sequencing…”
Get more information

Meeting highlights : international consensus panel on the treatment of primary breast cancer by GOLDHIRSCH, Aron, GLICK, John H, GELBER, Richard D, COATES, Alan S, SENN, Hans-Jörg

Get full text

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma by Glover, D, Glick, J H, Weiler, C, Fox, K, Guerry, D

“…Cisplatin, alone or in combination with other chemotherapeutic agents, is relatively inactive against metastatic melanoma. Prior trials have demonstrated…”
Get more information

Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study by Sparano, J A, Neuberg, D, Glick, J H, Robert, N J, Goldstein, L J, Sledge, G W, Wood, W

“…To determine the efficacy of a biweekly paclitaxel and cisplatin regimen in patients with advanced breast carcinoma, which has previously been reported to…”
Get more information

Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation by Weisdorf, D J, Andersen, J W, Glick, J H, Oken, M M

“…Despite modern therapy, patients with low-grade non-Hodgkin's lymphomas (NHLs) have a median survival of only 7 to 10 years. To determine factors that predict…”
Get more information

Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma by Fisher, Richard I, Gaynor, Ellen R, Dahlberg, Steve, Oken, Martin M, Grogan, Thomas M, Mize, Evonne M, Glick, John H, Coltman, Charles A, Miller, Thomas P

“…The development of curative combination chemotherapy for patients with advanced stages of aggressive non-Hodgkin's lymphoma has been one of the major successes…”
Get full text

A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study by Fisher, R I, Gaynor, E R, Dahlberg, S, Oken, M M, Grogan, T M, Mize, E M, Glick, J H, Coltman, Jr, C A, Miller, T P

“…CHOP is a four-drug, first-generation combination chemotherapy regimen that has cured approximately 30% of all patients with advanced stages of intermediate-…”
Get more information

Meeting highlights: adjuvant therapy for breast cancer by Glick, J H

Get more information

WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial by Glover, D, Glick, J H, Weiler, C, Hurowitz, S, Kligerman, M M

“…WR-2721 S-2-(3-aminopropylamino) ethyl phosphorothioic acid, is an organic thiophosphate compound that in the animal model selectively protects against the…”
Get more information